| |
| |
|
| Insider
Information: |
Wierenga Wendall D |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
167,585 |
|
|
Indirect Shares
|
15,373 |
|
|
| Direct
Value |
$7,005,532 |
|
|
|
Indirect Value
|
$1,634 |
|
|
| Total
Shares |
182,958 |
|
|
| Total
Value |
$7,007,166 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 122.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Neurocrine Biosciences Inc |
NBIX |
EVP, Research & Develo... |
2003-10-10 |
5,023 |
2003-09-01 |
0 |
Premium* |
|
|
Onyx Pharmaceuticals Inc |
ONXX |
Director |
2013-10-01 |
0 |
2003-11-03 |
0 |
Premium* |
|
|
Xenoport Inc |
XNPT |
Director |
2016-07-05 |
0 |
2006-12-15 |
0 |
Premium* |
|
|
Santarus Inc |
SNTS |
EVP, R&D |
2014-01-02 |
0 |
2014-01-02 |
0 |
Premium* |
|
|
Concert Pharmaceuticals, Inc. |
CNCE |
Director |
2014-03-13 |
12,389 |
|
0 |
Premium* |
|
|
Seelos Therapeutics Inc |
SEEL |
Director |
2014-10-22 |
20,000 |
2017-01-05 |
15,373 |
Premium* |
|
|
Ocera Therapeutics Inc |
OCRX |
Director |
2017-12-11 |
0 |
2015-06-23 |
0 |
Premium* |
|
|
Cytokinetics Inc |
CYTK |
Director |
2024-05-15 |
24,327 |
2020-04-28 |
0 |
Premium* |
|
|
Crinetics Pharmaceuticals, Inc. |
CRNX |
Director |
2023-06-16 |
105,846 |
2020-04-28 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
86 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2011-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
6,580 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2011-05-02 |
4 |
AS |
$37.67 |
$9,418 |
D/D |
(250) |
6,330 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2011-08-01 |
4 |
AS |
$33.27 |
$8,318 |
D/D |
(250) |
6,080 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2012-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
8,580 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2012-07-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
9,830 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2012-08-01 |
4 |
AS |
$74.76 |
$18,690 |
D/D |
(250) |
9,580 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2012-08-24 |
4 |
OE |
$27.14 |
$135,700 |
D/D |
5,000 |
14,580 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2012-08-24 |
4 |
S |
$74.09 |
$370,449 |
D/D |
(5,000) |
9,580 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2012-11-01 |
4 |
AS |
$77.21 |
$19,303 |
D/D |
(250) |
9,330 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2013-02-01 |
4 |
AS |
$77.71 |
$19,428 |
D/D |
(250) |
9,080 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2013-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
2,100 |
11,180 |
0 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2013-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
8,998 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2013-10-01 |
4 |
D |
$125.00 |
$1,135,000 |
D/D |
(9,080) |
2,100 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Director |
– • – |
2013-10-01 |
4 |
D |
$125.00 |
$262,500 |
D/D |
(2,100) |
0 |
0 |
- |
|
| SNTS |
Santarus Inc |
EVP, R&D |
• – – |
2014-01-02 |
4 |
D |
$32.00 |
$10,048 |
D/D |
(314) |
0 |
0 |
- |
|
| SNTS |
Santarus Inc |
EVP, R&D |
• – – |
2014-01-02 |
4 |
D |
$32.00 |
$150,848 |
D/D |
(4,714) |
0 |
0 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2014-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
13,998 |
0 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2014-05-27 |
4 |
B |
$3.99 |
$39,900 |
D/D |
10,000 |
23,998 |
2.39 |
- |
|
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2014-10-22 |
4 |
B |
$1.52 |
$30,364 |
D/D |
20,000 |
20,000 |
2.39 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2015-05-11 |
4 |
B |
$5.63 |
$28,169 |
D/D |
5,000 |
28,998 |
2.39 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2015-05-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
33,998 |
0 |
- |
|
| OCRX |
Ocera Therapeutics Inc |
Director |
– • – |
2015-06-23 |
4 |
B |
$3.71 |
$18,550 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2016-04-05 |
4 |
A |
$0.58 |
$2,813 |
I/I |
4,850 |
24,850 |
0 |
- |
|
| XNPT |
Xenoport Inc |
Director |
– • – |
2016-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
38,998 |
0 |
- |
|
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2016-06-30 |
4 |
A |
$0.40 |
$3,000 |
I/I |
7,510 |
32,360 |
0 |
- |
|
86 Records found
|
|
Page 2 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
